Share this article:
Maternal Obesity and Diabetes in Pregnancy Result in Early Overgrowth of the Baby in the Womb
The babies of obese women who develop gestational diabetes are five times as likely to be excessively large by six months of pregnancy, according to new research led by the University of Cambridge. The study, which shows that excessive fetal growth begins weeks before at-risk women are screened for gestational diabetes, suggests that current screening programmes may take place too late during pregnancy to prevent lasting health impacts on the offspring.
Gestational diabetes is a condition that can affect women during pregnancy, with those who are obese at greater risk. As well as affecting the mother’s health, the condition also causes the unborn child to grow larger, putting the mother at risk during childbirth and increasing the likelihood that her offspring will develop obesity and diabetes during later life. The condition can usually be controlled through a combination of diet and exercise, and medication if these measures fail.
Women are screened for the condition through a blood glucose test at around 8-12 weeks into pregnancy. Current guidelines in the UK and the USA recommend that mothers found to be at greatest risk should then be offered a full test at between 24 and 28 weeks into pregnancy; however, in practice the majority of women are screened at the 28 week mark.
Given the risk of complications for both mother and child from gestational diabetes, our findings suggest that screening women earlier on in pregnancy may help improve the short and long term outcomes for these women. – Gordon Smith
Researchers at the Department of Obstetrics & Gynaecology at the University of Cambridge analysed data from the Pregnancy Outcome Prediction study, which followed more than 4,000 first time mothers using ultrasound scans to assess the growth of their babies in the womb. They measured the abdominal and head circumference of the foetuses and compared the growth in women who developed gestational diabetes with those who did not. The results are published today in the journal Diabetes Care.
Of the 4,069 women studied, 171 (4.2%) were diagnosed with gestational diabetes at or beyond 28 weeks. The researchers found no association between the size of the child at 20 weeks and the mother subsequently developing gestational diabetes. However, they found that the foetuses of women subsequently diagnosed with gestational diabetes grew excessively prior to diagnosis, between 20 and 28 weeks. Hence, the babies were already large at the time of diagnosis, and their findings suggest that the onset of fetal growth disorder in gestational diabetes predates the usual time of screening.
The researchers also studied women who were obese, as it is well recognised that maternal obesity is a risk factor for childhood obesity. Even in the absence of diabetes, the babies of obese women were also twice as likely to be big at 28 weeks. The combination of obesity and gestational diabetes was associated with an almost 5-fold risk of excessive fetal growth by the 28 week scan.
“Our study suggests that the babies of women subsequently diagnosed with gestational diabetes are already abnormally large by the time their mothers are tested for the disease,” says Dr Ulla Sovio from the Department of Obstetrics and Gynaecology at the University of Cambridge, the study’s first author. “Given the risk of complications for both mother and child from gestational diabetes, our findings suggest that screening women earlier on in pregnancy may help improve the short and long term outcomes for these women.
“Early screening may be particularly beneficial for obese women, as fetal growth is already abnormal by 20 weeks among these women. Any intervention aimed at reducing the risk of abnormal birthweight in the infants of obese women may need to be implemented even earlier.”
Senior author Professor Gordon Smith, also from the University of Cambridge, adds: “We know that the offspring of women with gestational diabetes are at increased risk of childhood obesity, but so far no clinical trials have successfully demonstrated that screening and intervention in pregnancy reduces this risk. Our study suggests a possible explanation: screening and intervention is taking place when the effects of gestational diabetes are already manifested in the foetus.
“The evidence from our study indicates that there is an urgent need for trials to assess the effect of earlier screening, both on the outcome of the pregnancy and the long term health for the offspring.”
Janet Scott, Research and Prevention Lead for the stillbirth charity Sands said: “We know from recent enquiries that failure to screen for gestational diabetes currently plays a part in a significant number of potentially avoidable stillbirths at term. Good risk assessment is crucial to avoiding harm to mothers and babies and we welcome these important findings which have real potential to inform better antenatal care for these high risk pregnancies. We are delighted to have supported this research, funded with donations from bereaved families.”
The work was supported by the National Institute for Health Research (NIHR) Cambridge Comprehensive Biomedical Research Centre and SANDS (the stillbirth and neonatal death charity).
Sovio, U et al. Accelerated fetal growth prior to diagnosis of gestational diabetes mellitus: a prospective cohort study of nulliparous women. Diabetes Care; 8 April 2016; DOI 10.2337/dc16-0160
Credits: For image use please see separate credits above. This article was originally published on the University of Cambridge Website under a Creative Commons Attribution 4.0 International License. Read the original article here.
Visit the Elsevier Store to access content on obesity, disease prevention, reproductive health and more! Use discount code STC215 at checkout and save up to 30% on your very own copy!
Handbook of Fertility reviews studies of common conditions such as obesity and metabolic syndrome and their effect on fertility and reproductive health.
Obesity provides a comprehensive examination of fertility issues arising from male and female obesity.
Biomedicine & Biochemistry
The disciplines of biomedicine and biochemistry impact the lives of millions of people every day. Research in these areas has led to practical applications in cardiology, cancer treatment, respiratory medicine, drug development, and more. Interdisciplinary fields of study, including neuroscience, chemical engineering, nanotechnology, and psychology come together in this research to yield significant new discoveries. Elsevier’s biomedicine and biochemistry content spans a wide range of subject matter in various forms, including journals, books, eBooks, and online information services, enabling students, researchers, and clinicians to advance these fields. Learn more about our Biomedical and Biochemistry books here.